Compare GDOT & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDOT | DAWN |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.3M | 624.8M |
| IPO Year | 2010 | 2021 |
| Metric | GDOT | DAWN |
|---|---|---|
| Price | $12.98 | $8.39 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $11.00 | ★ $26.56 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,007,128,000.00 | $133,672,000.00 |
| Revenue This Year | $22.56 | $15.51 |
| Revenue Next Year | $11.63 | $49.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.16 | ★ 31.11 |
| 52 Week Low | $6.13 | $5.64 |
| 52 Week High | $15.41 | $13.53 |
| Indicator | GDOT | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 48.09 |
| Support Level | $12.88 | $8.13 |
| Resistance Level | $13.75 | $8.67 |
| Average True Range (ATR) | 0.42 | 0.48 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 61.31 | 24.73 |
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.